Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Section 4 of 6

Clinical evidence

416 evidence topics · 50 sources

Study summaries

Voyage

Objective
Location and study date
Registered study dates
FieldQuoted record
Study start (actual)“2024-12-11”
Primary completion (actual)“2026-07-15”
Study completion (estimated)“2027-04”
Recruitment status“Active, not recruiting”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using hamilton anxiety rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Analyzed: all randomized participants in the intention-to-treat population
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and baseline characteristics: ITT population
CharacteristicDT120 ODT (n = 107)Placebo ODT (n = 107)Overall (N = 214)
Age, mean (range), years“42 (21–72)”“43 (20–67)”“42 (20–72)”
Female, n (%)“63 (59)”“74 (69)”“137 (64)”
Male, n (%)“44 (41)”“33 (31)”“77 (36)”
White, n (%)“78 (73)”“77 (72)”“155 (72)”
Black or African American, n (%)“9 (8)”“19 (18)”“28 (13)”
Asian, n (%)“8 (7)”“9 (8)”“17 (8)”
Baseline HAM-A score, mean (SD)“28.4 (5.9)”“27.4 (5.5)”“27.9 (5.7)”
Moderate GAD (HAM-A <24), n (%)“26 (24)”“28 (26)”“54 (25)”
Severe GAD (HAM-A ≥24), n (%)“81 (76)”“79 (74)”“160 (75)”
Baseline CGI-S score, mean (SD)“4.6 (0.6)”“4.6 (0.6)”“4.6 (0.6)”
Past use of any psychedelic, n (%)“18 (17)”“27 (25)”“45 (21)”
Past LSD use, n (%)“10 (9)”“9 (8)”“19 (9)”
No past GAD medications, n (%)“35 (33)”“36 (34)”“71 (33)”
One past GAD medication, n (%)“31 (29)”“34 (32)”“65 (30)”
Two or more past GAD medications, n (%)“41 (38)”“37 (35)”“78 (36)”
Comorbid MDD, n (%)“43 (40)”“37 (35)”“80 (37)”
Years since GAD diagnosis, mean (SD)“11.1 (10.1)”“12.9 (11.6)”“12.0 (10.9)”
Years since onset of GAD symptoms, mean (SD)“21.9 (13.7)”“25.7 (14.4)”“23.8 (14.1)”
Baseline MADRS score
CharacteristicDT120 ODT (n=107)Placebo ODT (n=107)Overall (n=214)
MADRS score, mean (SD)“13.6 (4.6)”“13.5 (4.4)”“13.5 (4.5)”
Characteristics at Part B entry: interim analysis
CharacteristicDT120 ODT in Part A (n=62)Placebo ODT in Part A (n=75)Total (n=137)
Mean age (years)“40.9”“43.6”“42.3”
Sex, female (%)“52%”“68%”“61%”
Race (% white)“76%”“76%”“76%”
HAM-A score at Part B entry“16.8”“21.2”“n/a”
CGI-S score at Part B entry“3.6”“4.2”“n/a”
Efficacy results
Primary and key secondary endpoints: Part A
EndpointDT120 ODT 100 µgPlacebo ODTPlacebo-adjusted difference
HAM-A: LS mean change at Week 12 (primary)“-11.6”“-6.2”“-5.4 (p<.0001)”
CGI-S: LS mean change at Week 12 (key secondary)“-1.0”“-0.4”“-0.6 (p<.0001)”
HAM-A: LS mean change at Week 1 (key secondary)“-11.9”“-4.2”“-7.7 (p<.0001)”
CGI-S: LS mean change at Day 2 (key secondary)“-1.0”“-0.2”“-0.8 (p<.0001)”
Response, remission, and mild or better at Week 12
EndpointDT120 ODT 100 µgPlacebo ODTPlacebo-adjusted difference
HAM-A response rate (≥50%) at Week 12“43%”“16%”“27% (p<0.0001)”
HAM-A remission rate (≤7) at Week 12“14%”“4%”“10% (p=0.0222)”
HAM-A mild or better (<16) at Week 12“51%”“23%”“28% (p<0.0001)”
Subgroup analyses: placebo-adjusted change in HAM-A at Week 12
SubgroupPlacebo-adjusted change in LS mean (SE)
All participants“−5.4 (1.0)”
Time since GAD symptoms began <22 years (n = 107)“−5.9 (1.4)”
Time since GAD symptoms began ≥22 years (n = 107)“−4.7 (1.5)”
Previous GAD medications <2 (n = 136)“−4.2 (1.2)”
Previous GAD medications ≥2 (n = 78)“−5.6 (1.7)”
Male (n = 77)“−7.1 (1.7)”
Female (n = 137)“−5.5 (1.2)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events of special interest: topline presentation value
Adverse eventDT120 ODT (n=107)Placebo ODT (n=107)
Any Adverse Event of Special Interest (AESI)“100 (94%)”“30 (28%)”
TEAEs with incidence of 10% or more, on the dosing day and after it
TEAEDosing day: DT120 ODT (n=107)Dosing day: placebo ODT (n=107)After dosing day: DT120 ODT (n=107)After dosing day: placebo ODT (n=107)
Illusion“80 (75%)”“11 (10%)”“2 (2%)”“0”
Nausea“41 (38%)”“9 (8%)”“3 (3%)”“3 (3%)”
Euphoric mood“28 (26%)”“4 (4%)”“0”“0”
Headache“26 (24%)”“7 (7%)”“12 (11%)”“7 (7%)”
Feeling abnormal“21 (20%)”“3 (3%)”“0”“0”
Disorientation“19 (18%)”“2 (2%)”“1 (1%)”“0”
Dizziness“14 (13%)”“5 (5%)”“1 (1%)”“1 (1%)”
Crying“13 (12%)”“4 (4%)”“0”“0”
Thinking abnormal“12 (11%)”“1 (1%)”“0”“0”
Paraesthesia“12 (11%)”“4 (4%)”“0”“0”
Feeling of body temperature change“12 (11%)”“1 (1%)”“0”“0”
Anxiety“11 (10%)”“2 (2%)”“3 (3%)”“0”
Feeling of relaxation“8 (8%)”“12 (11%)”“1 (1%)”“0”
Hallucination, visual“9 (8%)”“2 (2%)”“1 (1%)”“0”
Insomnia“7 (7%)”“0”“1 (1%)”“6 (6%)”
Emotional disorder“6 (6%)”“1 (1%)”“1 (1%)”“0”
Study limitations
Summary
  • Publication status: results come from company topline announcements, presentations, and filings and from a report of the Voyage topline results; one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results.
  • Functional unblinding: Voyage used a two-arm design of DT120 100 µg versus placebo without the 50 µg low-dose comparator used in Panorama. Study drug-related TEAEs occurred in 95% of participants receiving DT120 and 48% receiving placebo, and illusion occurred on the dosing day in 75% and 10%. Baseline expectancy and perceived treatment were recorded; the cited disclosures report no results of these assessments. Central HAM-A raters were blinded to treatment assignment and visit number. Past psychedelic use was reported by 21% of participants.
  • Duration and dosing: the controlled comparison covers 12 weeks after a single dose. Part B is open label, and its results come from an interim analysis as of July 15, 2026, with 37 participants who received DT120 in Part A contributing HAM-A data at Week 28.
  • Comparator: placebo was the only comparator; no active GAD treatment was included. The placebo group improved by 6.2 points on HAM-A at Week 12.
  • Generalizability: participants were 18 to 74 years of age at approximately 35 sites in the United States, and people taking medications with anxiolytic or antidepressant effects that could not be discontinued, people with a personal or first-degree family history of psychotic or bipolar disorder, people with current alcohol or substance use disorder, and people in systematic psychotherapy within 4 weeks before screening were excluded.
  • Outcomes not reported in the cited disclosures: registered patient-reported, functioning, quality of life (PGI-S, WPAI-SHP, EQ-5D-5L), and sexual functioning (CSFQ-14) endpoints. The sponsor stated that Part B safety data are expected to be shared in a future presentation.
  • Discrepancies between sources: the share of participants clearing the end-of-session checklist by hour 8 is 92% in the topline announcement and 90% in the poster, and adverse events of special interest with DT120 are 100 (94%) in the topline presentation and 100 (93) in the poster.

Panorama

Objective
Location and study date
Study dates in the registry
MilestoneRegistry record
Study start (actual)“2025-01-29”
Primary completion (actual)“2026-08-13”
Study completion (estimated)“2027-05”
First posted“2025-02-05”
Last update posted“2026-09-04”
EU member state decision, trial start, and recruitment dates
Topline timing: second half of 2026, January 2025, superseded in April 2026
Study design
Eligibility criteria
Treatment
Single dose in Part A
Study outcomes
Rationale for using hamilton anxiety rating scale total score as the primary endpoint
Other registered secondary outcomes in Part A

“HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period” (opens the source at this quote in a new tab)

“HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period” (opens the source at this quote in a new tab)

“Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)” (opens the source at this quote in a new tab)

“Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)” (opens the source at this quote in a new tab)

“Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period” (opens the source at this quote in a new tab)

Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry
FieldRegistry record
Enrollment (actual)“245”
Planned maximum in the detailed description“The study will enroll up to 375 participants aged 18 to 74 years”
Planned enrollment: approximately 250 participants, January 2025, superseded in April 2026
Description of analysis sets
Results
Participant disposition
Part B enrollment in the extension population
Part A groupParticipants
DT120 ODT 100 µg“n=62”
DT120 ODT 50 µg control“n=33”
Placebo ODT“n=68”
Total“n=163”
Baseline characteristics
Demographics and baseline characteristics, ITT population
CharacteristicDT120 ODT 100 µg (n=96)DT120 ODT 50 µg control (n=52)Placebo ODT (n=97)Overall (n=245)
Mean age (years)“39.8”“40.4”“42.3”“40.9”
Sex (% female)“62%”“56%”“62%”“60%”
Race (% white)“82%”“85%”“84%”“83%”
Baseline HAM-A score, mean (SD)“28.3 (5.5)”“27.7 (4.8)”“28.0 (5.6)”“28.0 (5.4)”
Baseline CGI-S score, mean (SD)“4.7 (0.5)”“4.7 (0.6)”“4.7 (0.6)”“4.7 (0.6)”
Past use of any psychedelic, n (%)“11 (12%)”“8 (15%)”“16 (17%)”“35 (14%)”
Past use of LSD, n (%)“4 (4%)”“4 (8%)”“8 (8%)”“16 (7%)”
Disease severity, treatment history, and comorbidity, ITT population
CharacteristicDT120 ODT 100 µg (n=96)DT120 ODT 50 µg control (n=52)Placebo ODT (n=97)Overall (n=245)
HAM-A moderate (<24), n (%)“20 (21%)”“9 (17%)”“27 (28%)”“56 (23%)”
HAM-A severe (≥24), n (%)“76 (79%)”“43 (83%)”“70 (72%)”“189 (77%)”
No past GAD treatments, n (%)“29 (30%)”“14 (27%)”“17 (18%)”“60 (25%)”
One past GAD treatment, n (%)“20 (21%)”“15 (29%)”“22 (23%)”“57 (23%)”
Two or more past GAD treatments, n (%)“47 (49%)”“23 (44%)”“58 (60%)”“128 (52%)”
Comorbid MDD, n (%)“28 (29%)”“17 (33%)”“25 (26%)”“70 (29%)”
MADRS score, mean (SD)“13.3 (4.4)”“13.4 (4.5)”“13.5 (3.9)”“13.4 (4.2)”
Years since diagnosis of GAD, mean (SD)“6.9 (7.6)”“9.4 (11.4)”“9.9 (8.8)”“8.6 (9.0)”
Years since onset of GAD symptoms, mean (SD)“16.4 (12.6)”“18.2 (15.5)”“19.1 (13.4)”“17.8 (13.6)”
Characteristics at Part B entry
CharacteristicDT120 ODT 100 µg (n=62)DT120 ODT 50 µg control (n=33)Placebo ODT (n=68)Total (n=163)
Mean age (years)“39.5”“42.3”“42.8”“41.4”
Sex, female (%)“62.9%”“51.5%”“58.8%”“58.9%”
Race (% white)“82.3%”“87.9%”“83.8%”“84.0%”
HAM-A score at Part B entry“18.3”“21.6”“23.3”“21.1”
CGI-S score at Part B entry“3.7”“4.0”“4.2”“4.0”
Efficacy results
Primary, key secondary, and other secondary endpoints
EndpointDT120 ODT 100 µgPlacebo ODTPlacebo-adjusted difference
HAM-A: LS mean change at Week 12 (primary)“-9.8”“-4.7”“-5.1 (p<0.0001)”
CGI-S: LS mean change at Week 12 (key secondary)“-1.0”“-0.5”“-0.6 (p<0.0001)”
HAM-A: LS mean change at Week 1 (key secondary)“-9.8”“-4.5”“-5.3 (p<0.0001)”
CGI-S: LS mean change at Day 2 (key secondary)“-1.1”“-0.3”“-0.8 (p<0.0001)”
HAM-A response rate (≥50%) at Week 12“32%”“14%”“18% (p<0.05)”
HAM-A remission rate (≤7) at Week 12“15%”“4%”“12% (p<0.05)”
HAM-A mild or better (<16) at Week 12“35%”“17%”“19% (p<0.01)”
HAM-A change by visit, 100 µg and 50 µg arms
Visit100 µg: change from baseline50 µg: change from baseline100 µg: improvement over placebo50 µg: improvement over placebo
Week 1“-9.8”“-10.3”“-5.3”“-5.8”
Week 4“-12.3”“-8.8”“-7.0”“-3.5”
Week 8“-10.4”“-8.1”“-5.3”“-3.0”
Week 12“-9.8”“-8.3”“-5.1”“-3.6”
CGI-S change by visit, 100 µg and 50 µg arms
Visit100 µg: change from baseline50 µg: change from baseline100 µg: improvement over placebo50 µg: improvement over placebo
Day 2“-1.1”“-1.1”“-0.8”“-0.8”
Week 1“-1.2”“-1.3”“-0.7”“-0.8”
Week 4“-1.4”“-1.2”“-1.0”“-0.7”
Week 12“-1.1”“-0.9”“-0.6”“-0.4”
Odds ratios for response, remission, and mild or better at Week 12
Outcome at Week 12Odds ratio, DT120 ODT 100 µg vs placebo
Response (HAM-A ≥ 50% improvement)“Odds ratio: 2.9”
Remission (HAM-A ≤ 7)“Odds ratio: 4.2”
Mild or better (HAM-A < 16)“Odds ratio: 2.6”
Pooled standard deviation of the primary endpoint
ItemPanorama
Primary endpoint, DT120 vs placebo“-5.1”
Design“3 arms”
Baseline HAM-A“28.0”
Baseline MADRS“13.4”
Pooled endpoint SD“8.4”
Health-related quality of life and patient-reported outcomes
Results of patient-reported outcomes

No evidence found.

Safety results
TEAEs with incidence of 10% or more in the 100 µg arm, on and after dosing day
TEAEDosing day: 100 µg (n=96)Dosing day: 50 µg (n=51)Dosing day: placebo (n=97)After dosing day: 100 µg (n=96)After dosing day: 50 µg (n=51)After dosing day: placebo (n=97)
Illusion“65 (68%)”“31 (61%)”“12 (12%)”“3 (3%)”“0”“0”
Nausea“35 (37%)”“13 (26%)”“4 (4%)”“2 (2%)”“4 (8%)”“1 (1%)”
Headache“23 (24%)”“14 (28%)”“13 (13%)”“13 (14%)”“6 (12%)”“10 (10%)”
Euphoric mood“30 (31%)”“16 (31%)”“5 (5%)”“1 (1%)”“0”“0”
Fatigue“22 (23%)”“5 (10%)”“6 (6%)”“7 (7%)”“1 (2%)”“4 (4%)”
Dizziness“22 (23%)”“10 (20%)”“3 (3%)”“1 (1%)”“1 (2%)”“0”
Anxiety“16 (17%)”“7 (14%)”“7 (7%)”“6 (6%)”“3 (6%)”“5 (5%)”
Crying“20 (21%)”“6 (12%)”“0”“0”“1 (2%)”“0”
Feeling cold“14 (15%)”“2 (4%)”“6 (6%)”“0”“0”“1 (1%)”
Paraesthesia“13 (14%)”“4 (8%)”“3 (3%)”“0”“1 (2%)”“1 (1%)”
Time perception altered“13 (14%)”“4 (8%)”“1 (1%)”“0”“0”“0”
Feeling of relaxation“12 (13%)”“8 (16%)”“11 (11%)”“1 (1%)”“0”“0”
Inappropriate affect“12 (13%)”“4 (8%)”“0”“0”“0”“0”
Feeling hot“11 (12%)”“4 (8%)”“4 (4%)”“0”“0”“0”
Emotional disorder“8 (8%)”“3 (6%)”“3 (3%)”“3 (3%)”“0”“0”
Feeling abnormal“10 (10%)”“7 (14%)”“4 (4%)”“0”“0”“1 (1%)”
Restlessness“10 (10%)”“1 (2%)”“3 (3%)”“1 (1%)”“0”“1 (1%)”
Tremor“10 (10%)”“4 (8%)”“1 (1%)”“1 (1%)”“0”“0”
Study limitations
Summary

Panorama randomized 245 participants 2:1:2 to a single dose of DT120 ODT 100 µg (96), DT120 ODT 50 µg (52), or placebo (97), and its primary analysis compares the 100 µg arm with placebo only. The 50 µg arm was not designed or powered for statistical comparisons, so the placebo-adjusted changes of -3.5 at Week 4 and -3.6 at Week 12 in that arm, and the dose-response statements built on them, carry no hypothesis test. The primary endpoint difference of -5.1 points (d=0.64) exceeds the 2.5-point minimal clinically important difference used in the phase 2b trial and the sponsor's 4-point target product profile; in the presentation's comparison of its trials, Panorama had a pooled endpoint standard deviation of 8.4. The study had no active comparator.

The 50 µg arm was included to mitigate functional unblinding, yet 91% (50 µg) and 95% (100 µg) of participants correctly guessed assignment to drug; no placebo-arm guess rate was reported. HAM-A ratings were made by central raters blinded to treatment assignment and visit number, and FDA guidance states that functional unblinding can lead to expectation bias. The sponsor states that the results support the conclusion that the dose response is not attributable to functional unblinding.

The results come from sponsor topline disclosures (an announcement, a slide presentation, and a Form 10-Q), the registry record lists no results posted, and one author states that adoption will depend on full peer-reviewed reporting of the Voyage and Panorama topline results. These disclosures report no confidence intervals for the primary or key secondary endpoints. Response, remission, and mild-or-better rates (32% vs 14%, 15% vs 4%, 35% vs 17%) are other secondary endpoints outside the multiplicity-controlled key secondary endpoints. Subgroup analyses cover the 100 µg and placebo arms only, and the presentation states that small subgroups give unstable estimates. Patient-reported, functional, quality of life, and sexual functioning outcomes (PGI-S, WPAI-SHP, EQ-5D-5L, CSFQ-14) are registered but unreported.

Part B results come from an interim analysis as of August 11, 2026, based on partial data and subject to change, with open-label dosing and declining numbers of participants (87 at Week 12 and 27 at Week 28 in the response analysis); the 50 µg cohort was excluded for small numbers. The presentation reports two Part B denominators, 204 participants entering Part B (76, 42, and 86 by Part A group) and an extension population of 163 (62, 33, and 68), without stating how they differ. The sponsor states that Part B safety data are expected in a future presentation.

The enrolled population was 60% female and 83% white, aged 18 to 74 years, excluded a current major depressive episode, substance use disorder, and psychotic or bipolar disorder in the participant or a first-degree relative, and excluded systematic psychotherapy within 4 weeks before screening. The psychedelic use exclusion was later amended to any lifetime use; 35 participants (14%) reported past use of any psychedelic and 16 (7%) past use of LSD. Treatment history differed between arms: 60% of placebo participants and 49% of 100 µg participants had two or more past GAD treatments. Enrollment exceeded the target of 200 participants set after a blinded sample size re-estimation. The company reports approximately 32 study centers while the registry lists 36 locations. Participants were monitored for at least 8 hours on dosing day, and 94% of the 100 µg arm met end-of-session checklist criteria by hour 8. The methods report states that Definium Therapeutics funded the study and that all of its authors are company employees.

MMED008

Objective
Location and study date
Study dates in the registry
MilestoneRegistry record
Study start (actual)“2022-08-24”
Primary completion (actual)“2023-10-06”
Study completion (actual)“2023-11-27”
First posted“2022-06-07”
Results first posted“2025-03-20”
Study design
Registry design fields
FieldRegistry record
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Quadruple”
Phase“Phase 2”
Other study ID“MMED008”
Rationale for the dose levels and the placebo control
Eligibility criteria
Key exclusion criteria in the protocol: psychiatric history and substance use

“Prior history (lifetime diagnosis) or known first-degree relative (i.e., mother/father/full siblings) with a lifetime diagnosis of schizophrenia spectrum, or other psychotic disorder or bipolar disorder (bipolar I, bipolar II or cyclothymic disorder)” (opens the source at this quote in a new tab)

“Lifetime diagnosis of Posttraumatic Stress Disorder” (opens the source at this quote in a new tab)

“Other current psychiatric disorders that, in the opinion of the Investigator, may confound the results of the study (e.g., major depressive disorder, obsessive-compulsive disorder,” (opens the source at this quote in a new tab)

“History of alcohol or substance use disorder within 12 months prior to Screening (Visit 1) (includes diagnosis of alcohol or drug use disorder per the MINI)” (opens the source at this quote in a new tab)

“Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)” (opens the source at this quote in a new tab)

“Treatment with deep brain stimulation (DBS), vagus nerve stimulation (VNS), electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within 3 months prior to Screening (Visit 1) or a plan to receive treatment with any of these from the time of providing informed consent until End of Study” (opens the source at this quote in a new tab)

Treatment
Dosing session procedures and monitoring
Study outcomes
Rationale for using hamilton anxiety rating scale Dose-Response at week 4 as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Completion by arm in the registry
ArmStartedCompletedNot completed
Placebo“39”“26”“13”
Lysergide 25 µg“39”“29”“10”
Lysergide 50 µg“40”“29”“11”
Lysergide 100 µg“40”“33”“7”
Lysergide 200 µg“40”“30”“10”
Baseline characteristics
Baseline demographics and disease characteristics by arm
CharacteristicPlacebo (n = 39)25 µg (n = 39)50 µg (n = 36)100 µg (n = 40)200 µg (n = 40)
Age, median (IQR), y“37 (28.5-47.5)”View highlighted excerpt for this quote“35 (30.5-43.0)”View highlighted excerpt for this quote“47 (33.0-57.3)”View highlighted excerpt for this quote“41 (29.0-55.5)”View highlighted excerpt for this quote“38.5 (33.8-55.0)”View highlighted excerpt for this quote
Female, No. (%)“26 (66.7)”View highlighted excerpt for this quote“20 (51.3)”View highlighted excerpt for this quote“20 (55.6)”View highlighted excerpt for this quote“16 (40.0)”View highlighted excerpt for this quote“28 (70.0)”View highlighted excerpt for this quote
White, No. (%)“30 (76.9)”View highlighted excerpt for this quote“33 (84.6)”View highlighted excerpt for this quote“29 (80.6)”View highlighted excerpt for this quote“36 (90.0)”View highlighted excerpt for this quote“33 (82.5)”View highlighted excerpt for this quote
Black or African American, No. (%)“6 (15.4)”View highlighted excerpt for this quote“3 (7.7)”View highlighted excerpt for this quote“2 (5.6)”View highlighted excerpt for this quote“1 (2.5)”View highlighted excerpt for this quote“3 (7.5)”View highlighted excerpt for this quote
Hispanic or Latino, No. (%)“8 (20.5)”View highlighted excerpt for this quote“5 (12.8)”View highlighted excerpt for this quote“6 (16.7)”View highlighted excerpt for this quote“6 (15.0)”View highlighted excerpt for this quote“6 (15.0)”View highlighted excerpt for this quote
Time from GAD diagnosis, median (IQR), y“11.0 (4.5-18.8)”View highlighted excerpt for this quote“7.0 (3.2-14.0)”View highlighted excerpt for this quote“12.9 (6.0-17.4)”View highlighted excerpt for this quote“11.2 (3.1-20.3)”View highlighted excerpt for this quote“11 (5.8-20.7)”View highlighted excerpt for this quote
HAM-A score, mean (SD)“30.3 (6.6)”View highlighted excerpt for this quote“30.2 (6.1)”View highlighted excerpt for this quote“30.3 (5.7)”View highlighted excerpt for this quote“29.3 (6.4)”View highlighted excerpt for this quote“31.0 (7.0)”View highlighted excerpt for this quote
CGI-S score, mean (SD)“4.9 (0.6)”View highlighted excerpt for this quote“4.9 (0.8)”View highlighted excerpt for this quote“4.9 (0.6)”View highlighted excerpt for this quote“4.8 (0.8)”View highlighted excerpt for this quote“5.1 (0.7)”View highlighted excerpt for this quote
MADRS score, mean (SD)“27.6 (9.7)”View highlighted excerpt for this quote“25.4 (7.6)”View highlighted excerpt for this quote“27.7 (8.3)”View highlighted excerpt for this quote“26.5 (8.0)”View highlighted excerpt for this quote“28.9 (8.3)”View highlighted excerpt for this quote
Continued psychotherapy during trial, No. (%)“9 (23.1)”View highlighted excerpt for this quote“3 (7.7)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote“7 (17.5)”View highlighted excerpt for this quote
Comorbid major depression, No. (%)“17 (43.6)”View highlighted excerpt for this quote“12 (30.8)”View highlighted excerpt for this quote“17 (47.2)”View highlighted excerpt for this quote“18 (45.0)”View highlighted excerpt for this quote“15 (37.5)”View highlighted excerpt for this quote
Comorbid social anxiety disorder, No. (%)“9 (23.1)”View highlighted excerpt for this quote“6 (15.4)”View highlighted excerpt for this quote“5 (13.9)”View highlighted excerpt for this quote“4 (10.0)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote
Comorbid panic disorder, No. (%)“7 (17.9)”View highlighted excerpt for this quote“5 (12.8)”View highlighted excerpt for this quote“4 (11.1)”View highlighted excerpt for this quote“2 (5.0)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote
SSRI or SNRI taper at enrollment, No. (%)“25 (64.1)”View highlighted excerpt for this quote“25 (64.1)”View highlighted excerpt for this quote“28 (77.8)”View highlighted excerpt for this quote“21 (52.5)”View highlighted excerpt for this quote“16 (40.0)”View highlighted excerpt for this quote
Benzodiazepine taper at enrollment, No. (%)“9 (23.1)”View highlighted excerpt for this quote“6 (15.4)”View highlighted excerpt for this quote“9 (25.0)”View highlighted excerpt for this quote“2 (5.0)”View highlighted excerpt for this quote“14 (35.0)”View highlighted excerpt for this quote
Efficacy results
Primary endpoint: MCP-Mod dose-response for HAM-A change at Week 4

“A significant MM120 dose-response relationship was demonstrated at both week 4 (primary outcome) and week 8 (key secondary outcome) based on changes from baseline in HAM-A score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At week 4, the adjusted critical value was 2.032 and the candidate dose-response models of sigmoid Emax 1 through 4, Emax, and linear observed absolute test statistics of 3.294, 3.149, 3.133, 1.448, 3.471, and 2.971, respectively. Therefore, 5 of the 6 models, including the linear, Emax, and multiple sigmoid Emax variants, met the significance threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For the primary outcome, the dose-response relationship assessed using the MCP-Mod method for change in HAM-A score at week 4 was statistically significant for the 100-µg and the 200-µg dose groups vs placebo (least-squares mean difference, −5.0 points [95% CI, −9.6 to −0.4 points] with 100 µg of MM120 and −6.0 points [95% CI, −9.8 to −2.0 points] with 200 µg of MM120) but the 25-µg and 50-µg dose groups did not reach significance vs placebo (least-squares mean difference, −1.2 points [95% CI, −6.0 to 3.5 points] with 25 µg of MM120 and −1.8 points [95% CI, −7.6 to 4.0 points] with 50 µg of MM120)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Primary endpoint as posted on the registry
ArmMean change from baseline to Week 4, model averaging (95% CI)Mean difference from placebo (95% CI)
Placebo“-14.23 (-17.83 to -10.63)”Not applicable
Lysergide 25 µg“-15.35 (-17.62 to -13.09)”“-1.24 (-6.01 to 3.53)”
Lysergide 50 µg“-16.05 (-19.40 to -12.71)”“-1.82 (-7.65 to 4.00)”
Lysergide 100 µg“-19.22 (-21.73 to -16.70)”“-5.02 (-9.60 to -0.44)”
Lysergide 200 µg“-20.09 (-22.87 to -17.31)”“-5.95 (-9.84 to -2.06)”
HAM-A change from baseline by week: observed-case ANCOVA differences from placebo
Week25 µg50 µg100 µg200 µg
Week 1“−4.3 (−8.5 to −0.1)”View highlighted excerpt for this quote“−2.5 (−6.7 to 1.7)”View highlighted excerpt for this quote“−8.1 (−12.3 to −3.9)”View highlighted excerpt for this quote“−6.0 (−10.2 to −1.8)”View highlighted excerpt for this quote
Week 2“−3.4 (−7.5 to 0.8)”View highlighted excerpt for this quote“−1.5 (−5.7 to 2.8)”View highlighted excerpt for this quote“−7.1 (−11.3 to −2.9)”View highlighted excerpt for this quote“−7.5 (−11.6 to −3.3)”View highlighted excerpt for this quote
Week 4“−3.4 (−7.7 to 0.9)”View highlighted excerpt for this quote“−0.9 (−5.2 to 3.3)”View highlighted excerpt for this quote“−7.6 (−11.8 to −3.4)”View highlighted excerpt for this quote“−5.5 (−9.7 to −1.3)”View highlighted excerpt for this quote
Week 8“−2.9 (−7.6 to 1.8)”View highlighted excerpt for this quote“0.85 (−3.9 to 5.6)”View highlighted excerpt for this quote“−4.3 (−8.9 to 0.3)”View highlighted excerpt for this quote“−5.5 (−10.2 to −0.8)”View highlighted excerpt for this quote
Week 12“−4.3 (−9.3 to 0.8)”View highlighted excerpt for this quote“−3.2 (−8.2 to 1.9)”View highlighted excerpt for this quote“−7.7 (−12.6 to −2.8)”View highlighted excerpt for this quote“−7.4 (−12.4 to −2.4)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Sheehan Disability Scale total score at Week 12
ArmObserved mean (SD) change from baselineDifference from placebo in mean change95% CI of the difference
Placebo“-8.2 (8.61)”Not applicableNot applicable
Lysergide 25 μg“-10.8 (7.72)”“-2.59”“(-7.10 to 1.91)”
Lysergide 50 μg“-9.0 (9.17)”“-0.83”“(-5.70 to 4.03)”
Lysergide 100 μg“-15.1 (5.78)”“-6.86”“(-10.89 to -2.83)”
Lysergide 200 μg“-13.1 (7.51)”“-4.93”“(-9.33 to -0.53)”
EQ-5D-5L visual analog scale at Week 12
ArmObserved mean (SD) change from baselineDifference from placebo in mean change95% CI of the difference
Placebo“11.7 (18.24)”Not applicableNot applicable
Lysergide 25 μg“17.0 (18.53)”“5.31”“(-4.65 to 15.27)”
Lysergide 50 μg“13.2 (13.97)”“1.55”“(-7.34 to 10.45)”
Lysergide 100 μg“17.7 (13.68)”“6.04”“(-2.61 to 14.70)”
Lysergide 200 μg“17.3 (19.40)”“5.64”“(-4.37 to 15.65)”
Pittsburgh Sleep Quality Index global score at Week 12
ArmObserved mean (SD) change from baselineDifference from placebo in mean change95% CI of the difference
Placebo“-4.3 (4.22)”Not applicableNot applicable
Lysergide 25 μg“-5.5 (4.01)”“-1.25”“(-3.48 to 0.99)”
Lysergide 50 μg“-4.8 (3.88)”“-0.55”“(-2.77 to 1.67)”
Lysergide 100 μg“-5.9 (4.13)”“-1.64”“(-3.84 to 0.56)”
Lysergide 200 μg“-4.9 (4.11)”“-0.60”“(-2.83 to 1.62)”
Patient Global Impression of Severity and of Change at Week 12
ArmPGI-S difference from placebo in mean changePGI-S 95% CIPGI-C observed mean (SD)PGI-C difference from placeboPGI-C 95% CI
PlaceboNot applicableNot applicable“2.2 (0.98)”Not applicableNot applicable
Lysergide 25 μg“-0.34”“(-0.91 to 0.24)”“1.8 (0.71)”“-0.36”“(-0.83 to 0.10)”
Lysergide 50 μg“-0.30”“(-0.94 to 0.34)”“1.8 (1.00)”“-0.36”“(-0.90 to 0.17)”
Lysergide 100 μg“-0.47”“(-1.05 to 0.11)”“1.5 (0.67)”“-0.71”“(-1.16 to -0.25)”
Lysergide 200 μg“-0.37”“(-1.01 to 0.26)”“1.7 (0.98)”“-0.51”“(-1.04 to 0.01)”
Sexual dysfunction (ASEX) at Week 12
ArmFemales with sexual dysfunction, n (%)Males with sexual dysfunction, n (%)
Placebo“6 (33.3)”“1 (12.5)”
Lysergide 25 μg“4 (25.0)”“3 (23.1)”
Lysergide 50 μg“10 (66.7)”“1 (7.1)”
Lysergide 100 μg“6 (46.2)”“2 (10.0)”
Lysergide 200 μg“7 (33.3)”“0 (0)”
Safety results
Adverse events in the safety population by arm
Event, No. (%)Placebo (n = 39)25 µg (n = 39)50 µg (n = 40)100 µg (n = 40)200 µg (n = 40)
At least 1 TEAE“22 (56.4)”View highlighted excerpt for this quote“30 (76.9)”View highlighted excerpt for this quote“36 (90.0)”View highlighted excerpt for this quote“39 (97.5)”View highlighted excerpt for this quote“40 (100)”View highlighted excerpt for this quote
Any treatment-related TEAE“16 (41.0)”View highlighted excerpt for this quote“29 (74.4)”View highlighted excerpt for this quote“32 (80.0)”View highlighted excerpt for this quote“38 (95.0)”View highlighted excerpt for this quote“40 (100)”View highlighted excerpt for this quote
Moderate AE“10 (25.6)”View highlighted excerpt for this quote“12 (30.8)”View highlighted excerpt for this quote“20 (50.0)”View highlighted excerpt for this quote“23 (57.5)”View highlighted excerpt for this quote“28 (70.0)”View highlighted excerpt for this quote
Visual perception changes“4 (10.3)”View highlighted excerpt for this quote“18 (46.2)”View highlighted excerpt for this quote“30 (75.0)”View highlighted excerpt for this quote“37 (92.5)”View highlighted excerpt for this quote“40 (100)”View highlighted excerpt for this quote
Nausea“3 (7.7)”View highlighted excerpt for this quote“3 (7.7)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote“16 (40.0)”View highlighted excerpt for this quote“24 (60.0)”View highlighted excerpt for this quote
Headache“9 (23.1)”View highlighted excerpt for this quote“5 (12.8)”View highlighted excerpt for this quote“9 (22.5)”View highlighted excerpt for this quote“14 (35.0)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote
Euphoric mood“1 (2.6)”View highlighted excerpt for this quote“2 (5.1)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote“11 (27.5)”View highlighted excerpt for this quote“6 (15.0)”View highlighted excerpt for this quote
Mydriasis“1 (2.6)”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“7 (17.5)”View highlighted excerpt for this quote“8 (20.0)”View highlighted excerpt for this quote“4 (10.0)”View highlighted excerpt for this quote
Hyperhidrosis“0”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“4 (10.0)”View highlighted excerpt for this quote“9 (22.5)”View highlighted excerpt for this quote“5 (12.5)”View highlighted excerpt for this quote
Suicidal ideation reported as an adverse event in the registry
ArmAffected / at risk (%)
Placebo“1/39 (2.56%)”
Lysergide 25 μg“1/39 (2.56%)”
Lysergide 50 μg“2/40 (5.00%)”
Lysergide 100 μg“2/40 (5.00%)”
Lysergide 200 μg“0/40 (0.00%)”
Study limitations
Summary

The trial randomized 198 participants at 22 outpatient sites in the United States to a single dose of lysergide capsules (25, 50, 100, or 200 µg) or placebo, with 12 weeks of follow-up and no study-related psychotherapy. The phase 3 trials use an orally disintegrating tablet, so the phase 2b results were obtained with a different formulation.

  • Primary analysis and reported effect size: the prespecified MCP-Mod primary analysis with multiple imputation gave a least-squares mean difference from placebo at Week 4 of −5.0 points (95% CI, −9.6 to −0.4) for 100 µg. The 7.6-point difference (Cohen d = 0.88) that company announcements report for Week 4 is the publication's secondary outcome at Week 4. The publication states that change in HAM-A score from baseline was analyzed by analysis of covariance without imputation (observed cases only), while missing primary end point data were imputed by multiple imputation; the registry results state that missing data were not imputed for non-key secondary efficacy endpoints.
  • Multiplicity: only the primary and key secondary outcomes were controlled for type I error; other hypothesis tests, including the Week 12 difference of −7.7 points and the response and remission rates, were not adjusted for multiple comparisons.
  • Functional unblinding: the authors state that the perceptible drug effects may have led to unblinding, and approximately 85% of participants correctly identified assignment to active treatment. Efficacy was rated by central raters blinded to protocol, treatment allocation, and visit.
  • Dosing session monitors: two monitors were present throughout each session, and the authors state that confounding effects of interpersonal interactions remain a possibility.
  • Missing data: 147 of 198 randomized participants (74.2%) completed the study, and the authors describe the dropout rate as slightly higher than in studies of similar molecules.
  • Population: participants were physically healthy with limited psychiatric comorbidities, discontinued anxiolytic and antidepressant medications before dosing, and 83.0% were White; 18% received psychotherapy outside the trial.
  • Sample size: 36 to 40 participants per arm in the full analysis set; analyses by sex and other characteristics were not conducted because of insufficient statistical power.
  • Adverse event figures for visual perceptual changes, nausea, and headache in the company publication announcement differ from those in the journal article (for example, nausea at 100 µg 42.5% versus 40.0%).
Limitations stated in the publication

“Despite dosing session monitors explicitly not providing a systematic psychotherapeutic intervention, confounding effects of interpersonal interactions remain a possibility.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Second, the perceptible drug effects of MM120 may have led to unblinding, which could have influenced the outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Third, the primary outcome and key secondary outcome were strictly controlled for type I error, but the other hypothesis tests were not adjusted for multiple comparisons. Fourth, the dropout rate, though similar across groups, was slightly higher than in studies of similar molecules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This higher dropout rate may be due to the 12-week duration of the trial, the required discontinuation of GAD medications, and the absence of an extension phase with opportunities for open-label treatment. Fifth, the participants were physically healthy with limited psychiatric comorbidities, potentially enhancing the tolerability of transient AEs. Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies. Seventh, some participants engaged in psychotherapy outside the trial, which may have affected dosing-day experiences and efficacy outcomes, though this was the case for only 18% of participants. Eighth, the study population was inclusive in terms of sex and age but was racially and ethnically less diverse than the general population of people with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

LSD-assist

Objective
Location and study date
Study identifiers, dates, and status
Study design
Eligibility criteria
Inclusion criteria
CriterionQuoted registry text
Age“Age > 25 years.”
Anxiety diagnosis or severity“Meet DSM-IV criteria for anxiety disorder as indicated by the Structured Clinical Interview for the DSM (SCID)-IV or have a score of at least 40 on the state- or trait STAI scale at study inclusion.”
Proportion with life-threatening illness“40% or more of the participants should have a diagnosis of advanced-stage potentially fatal illness (autoimmune, neurological, or cancer without central nervous system (CNS) involvement).”
Life expectancy“Patients should be ambulatory and not terminal and likely to have a roughly estimated life expectancy of > twelve months.”
Participants without life-threatening illness“Patients without advanced-stage potentially fatal illness need to meet DSM-IV criteria for anxiety disorder (elevated STAI score not sufficient for inclusion)”
Psychiatric medication“Participants are willing to refrain from taking any psychiatric medications during the experimental session period.”
Washout of antidepressants and anxiolytics“If they are being treated with antidepressants or are taking anxiolytic medications on a fixed daily regimen such drugs must be discontinued long enough before the LSD/placebo treatment session to avoid the possibility of a drug-drug interaction (the interval will be at least 5 times the particular drug's half-life [typically 3-7 days]).”
Ongoing psychotherapy“If in ongoing psychotherapy, those recruited into the study may continue to see their outside therapist, provided they sign a release for the investigators to communicate directly with their therapist.”
Other psychoactive drugs“Participants must also refrain from the use of any psychoactive drugs, with the exception of the long term pain medication or caffeine or nicotine, within 24 hours of each LSD/placebo treatment session.”
Driving“Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD/placebo administration.”
Treatment
Study outcomes
Rationale for using State-Trait anxiety inventory global score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Follow-up analysis set and statistical model
Results
Participant disposition
Baseline characteristics
Efficacy results
Follow-up at 12 months: remission and response
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

NCT03153579 was an investigator-initiated phase 2 crossover trial at two centers in Switzerland (University Hospital Basel and a private practice in Solothurn), funded by University Hospital Basel and the Swiss Medical Society for Psycholytic Therapy. The registered summary planned 40 participants; 46 were enrolled, and 42 were included in the primary analysis. Because of carryover effects, the primary results are a between-subjects comparison of the first period, in which a STAI-G response (reduction of 30% or more) was reported for 13 of 20 participants (65%) receiving LSD and 2 of 22 (9%) receiving placebo. The response figures come from the May 2022 company announcement of an oral presentation; the primary publication reports the least-squares mean difference of -16.2 points (95% CI, -27.8 to -4.5) at 16 weeks.

The population combined participants with an anxiety disorder and participants with anxiety associated with a life-threatening illness, for whom a STAI score of 40 or more could substitute for a DSM-IV diagnosis; eligible diagnoses included generalized anxiety disorder, social phobia, and panic disorder, and the follow-up post hoc tests found no difference in STAI-G change between participants with and without a formal GAD diagnosis (P = 0.35 and P = 0.65). The primary endpoint was a self-reported questionnaire, and the follow-up authors state that no objective, interview-based data and no measure of expectancy were collected. The placebo-first group had higher symptom ratings at inclusion, a difference that remained throughout the trial.

Each participant received LSD 200 μg in two sessions of approximately 12 hours with one investigator or therapist, and study visits included talk therapy. The follow-up publication describes the study drug as LSD free base in an oral solution of 96% ethanol (100 μg per mL) with an ethanol-only placebo, while the registry describes placebo capsules containing mannitol. Most participants had received anxiolytics, antidepressants, or psychotherapy before entry, antidepressants were tapered only for the sessions, and the authors state that LSD served as an add-on treatment; the participants were described as having a long history of treatment attempts and failures, with anxiety diagnosed a mean of 10 years before inclusion.

The 12-month follow-up had no control group, since all participants had received LSD by then. Questionnaires were returned by mail by 35 participants, with 33 contributing STAI measures, and 6 participants continued psychedelic therapy in the Swiss limited-use programme with one to four additional LSD sessions. The authors state that it is largely unclear what therapy participants received between the end-of-study visit and follow-up. The primary publication reports transient, mild acute untoward effects in 8 participants (19%) and one treatment-related serious adverse event of acute transient anxiety (2%), which the company announcement describes as acute transient anxiety and delusions. The registry has no posted results.

Two authors are consultants for Mind Medicine, Inc., which licensed the knowhow and data owned by University Hospital Basel; the authors state that the company had no role in financing, planning, or conducting the follow-up study, and the company states that it has exclusive access and rights to the data.

LDA1

Objective
Location and study date
Study identifiers, dates, and status
ItemRegistry record
Other study ID“LDA1”
Phase“Phase 2”
Study start“2008-02”
Primary completion (actual)“2011-04-14”
Study completion (actual)“2012-09”
First posted (estimated)“2009-06-15”
Results first posted“2021-12-08”
Last update posted“2023-07-12”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using State-Trait anxiety inventory score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Registry participant flow
Period and statusFull dose LSD (200 mcg), blinded stage 1Active placebo LSD (20 mcg), stage 1Full dose LSD (200 mcg), open-label stage 2
Stage 1 started“8”“4”“0”
Stage 1 completed“7”“4”“0”
Stage 1 not completed: adverse event“1”“0”“0”
Stage 2 started“0”“0”“3”
Stage 2 completed“0”“0”“3”
Baseline characteristics
Registry baseline characteristics
CharacteristicFull dose LSD (200 mcg)Active placebo LSD (20 mcg)Total
Participants“8”“3”“11”
Age, years, mean (SD)“49.6(8.4)”“57.4(9.9)”“51.7(9.1)”
Female“3”“1”“4”
Male“5”“2”“7”
History of suicidal tendencies: none“8”“1”“9”
History of suicidal tendencies: mild“0”“2”“2”
Metastatic breast carcinoma“3”“1”“4”
Metastatic gastric carcinoma“2”“0”“2”
Plasmocytoma“1”“0”“1”
Non-Hodgkin's Lymphoma“0”“1”“1”
Celiac Disease“0”“1”“1”
Parkinson's Disease“1”“0”“1”
Bechterew's Disease“1”“0”“1”
Baseline STAI scores (registry primary outcome at baseline, visit 4)
STAI subscale, mean (SD)Full dose LSD (200 mcg), n = 8Active placebo LSD (20 mcg), n = 3
STAI-state“53.1(4.7)”“47.7(7.7)”
STAI-trait“53.2(4.3)”“43.3(7.0)”
Efficacy results
Primary endpoint: STAI at 2 months after the second session (registry)
STAI subscale, mean (SD)Full dose LSD (200 mcg), n = 8Active placebo LSD (20 mcg), n = 3
STAI-state“41.5(3.2)”“51.7(5.3)”
STAI-trait“45.2(3.7)”“49.0(6.1)”
Health-related quality of life and patient-reported outcomes
Safety results
Registry adverse events: mortality, serious, and selected other adverse events
Adverse event (affected / at risk)Full dose LSD (200 mcg), stage 1Active placebo LSD (20 mcg), stage 1Full dose LSD (200 mcg), stage 2
All-cause mortality“1/8 (12.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Serious adverse events, total“1/8 (12.50%)”“1/4 (25.00%)”“0/3 (0.00%)”
Serious: metastatic esophageal cancer“1/8 (12.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Serious: pyelonephritis“0/8 (0.00%)”“1/4 (25.00%)”“0/3 (0.00%)”
Other adverse events, total“8/8 (100.00%)”“4/4 (100.00%)”“3/3 (100.00%)”
Feeling cold“6/8 (75.00%)”“0/4 (0.00%)”“1/3 (33.33%)”
Illusions“6/8 (75.00%)”“1/4 (25.00%)”“2/3 (66.67%)”
Emotional distress“5/8 (62.50%)”“1/4 (25.00%)”“0/3 (0.00%)”
Feeling abnormal“5/8 (62.50%)”“2/4 (50.00%)”“1/3 (33.33%)”
Time perception altered“4/8 (50.00%)”“0/4 (0.00%)”“2/3 (66.67%)”
Mydriasis“3/8 (37.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Anxiety“2/8 (25.00%)”“2/4 (50.00%)”“1/3 (33.33%)”
Impaired gait“2/8 (25.00%)”“0/4 (0.00%)”“2/3 (66.67%)”
Hallucination“1/8 (12.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Study limitations
Summary

LDA1 was a phase 2 pilot trial at one private practice in Solothurn, Switzerland, with the Multidisciplinary Association for Psychedelic Studies (MAPS) named as main sponsor; MAPS co-funded the trial, and the funding statement names two MAPS employees. Twelve participants with anxiety associated with life-threatening diseases were randomized to LSD 200 μg (8 participants) or an active placebo of LSD 20 μg (4 participants); one active placebo participant was excluded from analysis after a correction of the qualifying diagnosis, leaving 8 and 3 participants. The authors state that the sample size was sufficient for a study primarily focused on safety and feasibility and that the limited sample reduced precision in effect size estimates and significance testing.

With the alpha level adjusted to 0.025 for multiplicity, the reduction in state anxiety (p = 0.021) met the threshold and the reduction in trait anxiety (p = 0.033) did not. Only three of eight participants in the 200 μg group fell below the threshold of 40 on each subscale. The assessment 1 week after the second session was dropped for all participants because results were missing for two participants, and secondary outcomes were not tested for significance. The 12-month comparisons included participants who received 200 μg in the open-label crossover and had no concurrent control, and the qualitative follow-up tested 10 participants.

Blinding was not maintained: for all 24 blinded sessions, all participants correctly guessed the dose, and the authors state that the 20-μg dose was too low to achieve uncertainty about the dose. Half of the participants received a SCID diagnosis of generalized anxiety disorder, and the authors state that this does not mean the participants had the conventional pattern of psychopathology usually associated with GAD, because the SCID items do not differentiate GAD from a reaction to a life-threatening disease. The registry lists the illnesses as metastatic breast carcinoma (4 participants), metastatic gastric carcinoma (2), and plasmocytoma, non-Hodgkin's lymphoma, celiac disease, Parkinson's disease, and Bechterew's disease (1 each); mean age was 51.7 years, 7 of 11 participants were male, and race and ethnicity were not collected. The authors state that the course of the somatic illness may affect psychological parameters independent of the intervention, and that the EORTC-QLQ focused on physical aspects and was insufficient for evaluating long-term psychological changes.

The intervention combined LSD capsules with two preparatory psychotherapy sessions, three drug-free integrative psychotherapy sessions after each experimental session, and a male and female co-therapist team, with 8-hour experimental sessions and an overnight stay. The publication reports no drug-related severe adverse events; the registry reports serious adverse events of metastatic esophageal cancer (1 of 8) and pyelonephritis (1 of 4) and all-cause mortality of 1 of 8 in the 200 μg group. The registry and the publication differ on two details: the registry requires a score of at least 40 on each part of the STAI and spaces sessions two to four weeks apart, while the publication states that participants scored greater than 40 on either the state or the trait scale and that sessions were 2 to 3 weeks apart.

MM-120-101

Objective
Location and study date
Registry record
ItemRegistry record
Scientific title“Phase I trial: MM-120-101”
IRAS number“1007602”
Sponsor“Mind Medicine Inc”
Countries of recruitment“United Kingdom”
Participating centre“MAC Clinical Research Liverpool”
Participating centre“MAC Clinical Research Manchester”
Date of first enrolment“13/10/2023”
Date of final enrolment“04/12/2023”
Completion date“19/12/2023”
Overall study status“Deferred”
Study design
Registry design description
ItemRegistry record
Study design“Phase 1 study in 30 healthy volunteers”
Primary study design“Other”
Phase“Phase I”
Intervention type“Drug”
Eligibility criteria
Registry eligibility fields
ItemRegistry record
Participant type“Healthy volunteer”
Age group“Adult”
Sex“All”
Health condition studied“Healthy volunteers”
Treatment
Study outcomes
Rationale for using plasma pharmacokinetic parameters as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size
ItemRegistry record
Target sample size at registration“30”
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Pharmacokinetic parameters by formulation
PK parameterMM120 capsuleMM120 ODT
Tmax (hr)“2.25”“2.0”
Cmax (ng/mL)“2.63”“2.68”
AUC0-∞ (ng*hr/mL)“15.7”“18.7”
AUC>1ng/mL (ng*hr/mL)“9.7”“12.0”
Geometric mean ratios relative to the capsule
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events in the pooled safety poster
MeasurePhase 1 PK bioavailability study, DT120 ODT (n = 29)
Any TEAE“25 (86.2)”
Mild“15 (51.7)”
Moderate“9 (31.0)”
Severe“1 (3.4)”
Study limitations
Summary

MM-120-101 was an open-label, randomized, two-period crossover study in healthy adults aged 18 to 55 years; it measured plasma pharmacokinetics, subjective effects, and adverse events, and enrolled no participants with GAD. Of 30 planned participants, 29 were randomized and 24 received both formulations; the pharmacokinetic analysis used those 24. Each formulation was given once at 100 µg, so the study does not inform repeated dosing or other dose levels.

Results come from an abstract, company presentations, and a safety analysis across four DT120 studies; publication of the registry record's full details is deferred to 19/12/2028. Sources differ on the pharmacokinetic summary: the abstract reports Cmax as similar, an AUC geometric mean ratio 16% higher with the ODT, and bioavailability similar to the capsule, while a company presentation describes 17% improved bioavailability (a geometric mean ratio of 1.17), a 23% increase in AUC at target concentration, and reduced gastrointestinal side effects based on a comparison between the phase 2b capsule study and this study. Sources also differ on adverse events with the ODT: the abstract reports 23 participants (79.3%) with TEAEs after the ODT, and the pooled safety poster reports 25 (86.2%) in a column labeled DT120 ODT (n = 29). The company's annual report states that the bridging study was completed in 2024, while the registry gives a completion date of 19/12/2023. The annual report states that the change in formulation could cause the product to perform differently, and one author names formulation bridging among the conditions on which adoption will depend.